Skip to content

Leadership

Evox has assembled an experienced, multidisciplinary team with deep and broad expertise spanning all aspects from early research and development to intellectual property and commercialisation of novel drug modalities. We believe in creating an open and transparent environment where we foster and leverage collaboration and innovation while having a singular focus on our mission to improve the lives of patients suffering from severe diseases.

Dr Antonin de Fougerolles

Chief Executive Officer

Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market and in helping build several multi-billion dollar companies from start-up stage.

Simon Dew

VP Business Development

Simon has over 20  years’ experience in pharmaceutical Business Development, Product Portfolio Strategy, Corporate Strategy and operational experience in international markets. Before joining Evox he was VP Corporate Strategy at Gyroscope Therapeutics and held leadership roles at Astellas in Corporate Strategy and Business Development. 

Bo Kara

VP Process Development

Bo has over 30 years’ experience in the biotechnology industry. He has expertise in the development of CMC for a wide range of protein, viral vector and cell therapy medicinal products. Prior to joining Evox Therapeutics, Bo was Head Process Development, Cell Gene Therapy at GSK.

Dr Per Lundin

Co-Founder and Chief Operating Officer

Per has over 10 years of experience in advising, founding and leading biotech companies developing groundbreaking therapies. Prior to co-founding Evox in 2016, he founded and led a cell therapy company, practiced patent law as a European Patent Attorney and worked in business development and consulting.

Dr David Virley

Head of Research

David has over 20 years’ experience in the bio-pharmaceutical and R&D industry. He has expertise in advancing neuroscience-based programs to the clinic for a range of CNS disorders. Prior to joining Evox Therapeutics, David was Head of Pharmacology at AbbVie in Germany.

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.